[go: up one dir, main page]

BRPI0408500A - tratamento do diabetes do tipo 1 com inibidores de pde5 - Google Patents

tratamento do diabetes do tipo 1 com inibidores de pde5

Info

Publication number
BRPI0408500A
BRPI0408500A BRPI0408500-0A BRPI0408500A BRPI0408500A BR PI0408500 A BRPI0408500 A BR PI0408500A BR PI0408500 A BRPI0408500 A BR PI0408500A BR PI0408500 A BRPI0408500 A BR PI0408500A
Authority
BR
Brazil
Prior art keywords
type
diabetes
pde5 inhibitors
diabetes treatment
treatment
Prior art date
Application number
BRPI0408500-0A
Other languages
English (en)
Inventor
Gillian Munro Burgess
Earl Michael Gibbs
Christopher Peter Wayman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0408500A publication Critical patent/BRPI0408500A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DO DIABETES DO TIPO 1 COM INIBIDORES DE PDE5". O uso de um inibidor de PDE5 sem atividade substancial de inibição de PDE2, ou um sal farmaceuticamente aceitável do mesmo na preparação de um medicamento para o tratamento do Diabetes do Tipo 1. Um método para tratar o diabetes do tipo 1 em um indivíduo sofrendo de diabetes do Tipo 1, cujo método compreende a administração ao referido indivíduo de uma quantidade eficaz de um inibidor de PDE5 sem atividade substancial de inibição de PDE2,ou de um sal farmaceuticamente aceitável do mesmo.
BRPI0408500-0A 2003-03-17 2004-03-04 tratamento do diabetes do tipo 1 com inibidores de pde5 BRPI0408500A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45527703P 2003-03-17 2003-03-17
PCT/IB2004/000696 WO2004082667A1 (en) 2003-03-17 2004-03-04 Treatment of type 1 diabetes with pde5 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0408500A true BRPI0408500A (pt) 2006-03-07

Family

ID=33029981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408500-0A BRPI0408500A (pt) 2003-03-17 2004-03-04 tratamento do diabetes do tipo 1 com inibidores de pde5

Country Status (7)

Country Link
EP (1) EP1605925A1 (pt)
JP (1) JP2006520777A (pt)
BR (1) BRPI0408500A (pt)
CA (1) CA2519357A1 (pt)
MX (1) MXPA05009242A (pt)
TW (1) TW200503666A (pt)
WO (1) WO2004082667A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234068A1 (en) * 2004-04-19 2005-10-20 Baldwin Dalton D Composition and method of decreasing renal ischemic damage
EP1909793A2 (de) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben
EP1922065A4 (en) * 2005-08-04 2009-11-11 Transform Pharmaceuticals Inc NEW FORMULATIONS WITH FENOFIBRATE AND A STATIN AND RELEVANT TREATMENT PROCESS
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
US8604245B2 (en) 2007-06-04 2013-12-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
CN108295058A (zh) * 2012-11-13 2018-07-20 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
BR112015015258A2 (pt) 2012-12-24 2017-09-26 Neurogastrx Inc métodos para tratar distúrbios do trato gastrintestinal
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023091A2 (en) * 1998-10-15 2000-04-27 Bioimage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
IL153426A0 (en) * 2000-06-30 2003-07-06 Pfizer Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
CN1446084A (zh) * 2000-08-11 2003-10-01 辉瑞大药厂 胰岛素抗性综合症的治疗
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
GB0106631D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
CA2436911A1 (en) * 2001-03-16 2002-09-26 Pfizer Inc. Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations

Also Published As

Publication number Publication date
TW200503666A (en) 2005-02-01
CA2519357A1 (en) 2004-09-30
WO2004082667A1 (en) 2004-09-30
JP2006520777A (ja) 2006-09-14
EP1605925A1 (en) 2005-12-21
MXPA05009242A (es) 2006-04-18

Similar Documents

Publication Publication Date Title
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
TW200639159A (en) Treatment of pain
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
CA2632207C (en) Use of calcitonin for the treatment of ra
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
BR0307410A (pt) Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
TW200742580A (en) Methods for treating nephrolithiasis
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
BR112015012497A2 (pt) combinações farmacêuticas
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired